Additional Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Palliative Treatment of Stage IV Colorectal Cancer Patients

Frank Gansauge, Thea Hamma, Helga Bach and Bertram Poch

Center for Oncologic, Endocrine and Minimal-Invasive Surgery, Germany
Shanxi University, Taiyuan, China
LDG - Laboratories Dr. Gansauge - GmbH, Germany

^*Correspondance to: Frank Gansauge 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: Despite improved chemotherapeutic approaches stage IV Colorectal Cancer (CRC) still has a poor prognosis with 5-year survival rates below 10 percent and a median overall survival below 20 months. Here we retrospectively analyzed the outcome of immunotherapy in the additional adjuvant treatment of stage IV CRC with Long Antigen Exposition Dendritic Cell therapy (LANEXDC®) in 73 patients who were treated at our surgical department.
Patients: Data were available of 73 patients. Dendritic cells (LANEX-DC®) were produced according to a recently published protocol.
Results: Therapy was well tolerated and no serious side effects were observed. Three year survival and five year survival were 38.7% and 23.3% respectively. The median survival time was 27.8 months.
Conclusion: We were able to show in a cohort of patients that additional treatment with dendritic cells (LANEX-DC®) is highly effective and increase the 5-year survival and the median survival time in the palliative treatment of stage IV CRC cancer patients.

Keywords:

Colorectal cancer; Dendritic cells; LANEX-DC®; Immunotherapy; Stage IV; Palliative

Cite the Article:

Gansauge F, Hamma T, Bach H, Poch B. Additional Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®)
in the Palliative Treatment of Stage IV Colorectal Cancer Patients. Clin Oncol. 2022;7:1942..